インスリノーマ治療の世界市場2019-2023

◆英語タイトル:Global Insulinoma Treatment Market 2019-2023
◆商品コード:IRTNTR30576
◆発行会社(リサーチ会社):Technavio
◆発行日:2018年12月27日
◆ページ数:114
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥267,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥321,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、インスリノーマ治療の世界市場について調査・分析し、市場概要、市場環境、インスリノーマ治療市場規模、種類別(手術、薬、その他)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・インスリノーマ治療の世界市場概要
・インスリノーマ治療の世界市場環境
・インスリノーマ治療の世界市場動向
・インスリノーマ治療の世界市場規模
・インスリノーマ治療の世界市場:業界構造分析
・インスリノーマ治療の世界市場:種類別(手術、薬、その他)
・インスリノーマ治療の世界市場:地域別市場規模・分析
・インスリノーマ治療の北米市場規模・予測
・インスリノーマ治療のヨーロッパ・中東・アフリカ市場規模・予測
・インスリノーマ治療のアジア太平洋市場規模・予測
・インスリノーマ治療の主要国分析
・インスリノーマ治療の世界市場:意思決定フレームワーク
・インスリノーマ治療の世界市場:成長要因、課題
・インスリノーマ治療の世界市場:競争環境
・インスリノーマ治療の世界市場:関連企業情報(ベンダー分析)
【レポートの概要】

About this market
Advances in laparoscopic treatment and diagnostic techniques have a considerable impact on the global insulinoma treatment market. This high cost of treatment, however, is a major challenge to the treatment of insulinoma, thus reducing patient adherence. Many government and non- government organizations, including companies are focusing on providing funding and grants as well as clinical assistance of ten treatment of various neuroendocrine tumors. Such funding programs encourage more patients to avail the treatment, which, in turn, increase the patient base. Such programs help patients adhere to the treatment regimen, even it is a long- term procedure. Technavio’s analysts have predicted that the insulinoma treatment market will register a CAGR of over 4% by 2023.
Market Overview
Advanced diagnostic techniques
Insulinoma is one of the key segments of the neuroendocrine tumors. Therefore, such advance in the field of diagnosis of neuroendocrine tumors will have a positive impact on the global insulinoma treatment market.
Shortage of patients volunteering of clinical trails
Numerous patients volunteer to participate in clinical trails, which has led to many innovations in disease prevention and treatment over the years. Without the willingness of the participating patients, many other people would have suffered with disease.
For the detailed list of factors that will drive and challenge the growth of the insulinoma treatment market during the 2019-2023, view our report.
Competitive Landscape
The global insulinoma treatment market is moderately concentrated, and as the market is in a growth phase, the competition is intense. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Surgery – Market size and forecast 2018-2023
• Drugs – Market size and forecast 2018-2023
• Other treatments – Market size and forecast 2018-2023
• Market opportunity by type
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 10: MARKET TRENDS
PART 11: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 12: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Ipsen Pharma
• Johnson & Johnson
• Novartis
• Pfizer
• Teva Pharmaceutical Industries
PART 13: APPENDIX
• Research methodology
• List of abbreviations

Exhibit 01: Years in consideration
Exhibit 02: Global oncology therapeutics market
Exhibit 03: Segments of global oncology therapeutics market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Type – Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Surgery – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Surgery – Year-over-year growth 2019-2023 (%)
Exhibit 22: Drugs – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Drugs – Year-over-year growth 2019-2023 (%)
Exhibit 24: Other treatments – Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Other treatments – Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by type
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 31: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in Americas
Exhibit 33: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in EMEA
Exhibit 36: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 37: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in APAC
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity
Exhibit 41: Decision framework
Exhibit 02: Impact of drivers and challenges
Exhibit 04: Vendor landscape
Exhibit 05: Landscape disruption
Exhibit 06: Vendors covered
Exhibit 07: Vendor classification
Exhibit 08: Market positioning of vendors
Exhibit 09: Ipsen Pharma – Vendor overview
Exhibit 10: Ipsen Pharma – Business segments
Exhibit 11: Ipsen Pharma – Organizational developments
Exhibit 12: Ipsen Pharma – Geographic focus
Exhibit 13: Ipsen Pharma – Segment focus
Exhibit 14: Ipsen Pharma – Key offerings
Exhibit 15: Ipsen Pharma – Key customers
Exhibit 16: Johnson & Johnson – Vendor overview
Exhibit 17: Johnson & Johnson – Business segments
Exhibit 18: Johnson & Johnson – Organizational developments
Exhibit 19: Johnson & Johnson – Geographic focus
Exhibit 20: Johnson & Johnson – Segment focus
Exhibit 21: Johnson & Johnson – Key offerings
Exhibit 22: Johnson & Johnson – Key customers
Exhibit 23: Novartis – Vendor overview
Exhibit 24: Novartis – Business segments
Exhibit 25: Novartis – Organizational developments
Exhibit 26: Novartis – Geographic focus
Exhibit 27: Novartis – Segment focus
Exhibit 28: Novartis – Key offerings
Exhibit 29: Novartis – Key customers
Exhibit 30: Pfizer – Vendor overview
Exhibit 31: Pfizer – Business segments
Exhibit 32: Pfizer – Organizational developments
Exhibit 33: Pfizer – Geographic focus
Exhibit 34: Pfizer – Segment focus
Exhibit 35: Pfizer – Key offerings
Exhibit 36: Pfizer – Key customers
Exhibit 37: Teva Pharmaceutical Industries – Vendor overview
Exhibit 38: Teva Pharmaceutical Industries – Business segments
Exhibit 39: Teva Pharmaceutical Industries – Organizational developments
Exhibit 40: Teva Pharmaceutical Industries – Geographic focus
Exhibit 41: Teva Pharmaceutical Industries – Segment focus
Exhibit 42: Teva Pharmaceutical Industries – Key offerings
Exhibit 43: Teva Pharmaceutical Industries – Key customers
Exhibit 44: Validation techniques employed for market sizing
Exhibit 45: List of abbreviations



【掲載企業】

Ipsen Pharma
Johnson & Johnson
Novartis
Pfizer
Teva Pharmaceutical Industries

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[インスリノーマ治療の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆